Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors

Sponsor: Bristol-Myers Squibb
Study ID: NCT02534506
Phase: PHASE1
Status: Completed

Conditions

Malignant Tumors

Eligibility Criteria

Sex: ALL
Age: 20 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Urelumab — DRUG
Nivolumab — DRUG

Study Details

The purpose of this study is to assess the safety and tolerability of BMS-663513 in subjects with advanced and/or metastatic malignant tumors.

Key Dates

Start date: Nov 6, 2015
Status verified: May 2020
Primary completion: Nov 11, 2016
Completion: Nov 11, 2016

Study Design

Enrollment: 18 participants (estimated)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: Urelumab (+ Nivolumab) intravenous (IV) infusion

Primary Outcome Measure

Safety of urelumab monotherapy as measured by the dose limiting toxicity (DLT) in subjects with advanced and/or metastatic malignant tumors [ Time Frame: From day 1 of treatment up to 60 days of follow-up ]